HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
Cardio 2024

Study residual cardiovascular risk of ApoB, HDL-C LDL-C CRP and Lpa in ischemic and non ischemic heart disease

Agustin Joison, Speaker at Cardiology Conferences
Cordoba Catholic University, Argentina
Title : Study residual cardiovascular risk of ApoB, HDL-C LDL-C CRP and Lpa in ischemic and non ischemic heart disease

Abstract:

Introduction: An understanding of the association between apolipoprotein B (Apo-B) and CRP (C-reactive protein) in the development of residual cardiovascular risk is very important when comparing it with atherogenic lipoproteins such as HDL-cholesterol, LDL-cholesterol. Apolipoprotein Apo-B and Lpa (lipoprotein pa)  were better predictors of cardiovascular desease than total cholesterol, LDL cholesterol, and non-HDL cholesterol.

Method: 24 patients with and without ischemic heart disease were studied to evaluate residual cardiovascular risk. For this, the levels of apoliprotein B, HDL-C, LDL-C, Lpa and CRP were analyzed and compared. Negative values indicate low residual cardiovascular risk index. Positive values indicate low residual cardiovascular risk index

Results: Lpa levels showed higher residual risk in patients with ischemic heart disease respect non ischemic heart disease 0,88 ± 0,44 vs -0,79 ± 0,013  (p<0.05). But no differences were found regarding ApoB 0.76 ± 0.44 vs 0.31 ± 0.41 (p> 005). LDL-Col levels showed higher residual risk in ischemic heart disease respect non ichemic heart disease 1,32 ± 0,46 vs -0,66 ± 0,13 (p < 0.05). CRP values showed higher residual risk in ischemic heart disease respect non ichemic heart disease 0,79 ± 0,48 vs -0,44 ± 0,21 (p<0.05). In ischemic heart disease, the residual risk is higher when measuring Lpa respect to LDL-C 0,88 ± 0,44 vs -0,66 ± 0,13 (p< 0.05).

Conclusion: Lipoprotein a and C-reactive protein were shown to be more efficient in the evaluation of residual risk in coronary ischemic disease.

Audience Take Away:

  • It is important to understand the dynamics in the evaluation of cardiovascular risk based on the measurement of biomarkers
  • Of course, the simplicity of the evaluation regarding cardiovascular risk in a predictive way and its prevention in a non-invasive way
  • With these results, a database can be created for the use of artificial intelligence and its use in predictive models

Biography:

Dr. Joison studied biochemistry at Cordoba National, Argentina and graduated as Clinical Biochemistry in 1980. He then joined the research group of  Health Science Faculty, Cordoba Catholic University as assistant and researcher. He received her PhD degree in 2017 at Cordoba National University. He has published more than 25 research articles in different Journals.

Watsapp